Melanotan II

Also: Melanotan II, Melanotan 2, MT-II, MT-2, MTII

Peptide ProfileLimitedStudied primarily in preclinical (in vitro and animal) and mechanistic contexts and characterized as a non-selective melanocortin receptor agonist. Not approved for human or veterinary use and referenced only as a research-use-only compound. Human data are limited and require independent editorial and source verification.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

Melanotan II is a synthetic cyclic heptapeptide described in the research literature as a non-selective analog of alpha-melanocyte-stimulating hormone (α-MSH) that is characterized as an agonist at melanocortin receptors. It appears primarily in preclinical and mechanistic studies of melanocortin signaling. It is referenced here only as a research-use-only compound; it is not approved for human or veterinary use, and the available evidence is limited and requires careful interpretation due to study-design and translation limitations.

Mechanism as described in the literature

Melanotan II is characterized in the research literature as a synthetic, cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH) that has been studied as a non-selective agonist across melanocortin receptor subtypes, including MC1R, MC3R, MC4R, and MC5R. In vitro and animal-model work describes how binding at these receptors engages downstream signaling pathways (such as cyclic AMP) that are examined in the context of melanocortin biology.

Because it is reported to engage multiple receptor subtypes rather than a single target, the mechanistic effects observed in preclinical systems are broad and difficult to attribute to any one pathway. Mechanisms described in vitro and in animal models do not establish outcomes in humans, and translation from these models remains uncertain.

Research areas

Melanocortin receptor (MC1R-MC5R) pharmacology and signaling
Preclinical melanogenesis and pigmentation biology
Central melanocortin pathways studied in animal models of energy homeostasis
Structure-activity relationships of α-MSH peptide analogs
Receptor selectivity and binding characterization in vitro

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is Melanotan II?+

It is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that is studied in preclinical research as a non-selective melanocortin receptor agonist. It is referenced as a research-use-only material and is not an approved drug.

Is Melanotan II the same as Melanotan I?+

No. They are distinct molecules. Melanotan I (afamelanotide) is a separate, structurally different α-MSH analog. Sources sometimes use these names loosely, so the specific compound should be verified against primary references.

What is the state of the evidence?+

The published literature is mostly preclinical and mechanistic. Human evidence is limited, and findings should be interpreted cautiously given study-design and translation constraints. References here are left empty for independent editorial verification.